Literature DB >> 11105175

Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.

S Johnson1, J G Baraboutis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11105175     DOI： 10.1001/jama.284.21.2722

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

Review 1.  Antiretroviral therapy in pregnancy: a focus on safety.

Authors:  G P Taylor; N Low-Beer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Transmission and postexposure management of bloodborne virus infections in the health care setting: where are we now?

Authors:  B W Moloughney
Journal:  CMAJ       Date:  2001-08-21       Impact factor: 8.262

3.  Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.

Authors:  June M McKoy; Charles L Bennett; Marc H Scheetz; Virginia Differding; Kevin L Chandler; Kimberly K Scarsi; Paul R Yarnold; Sarah Sutton; Frank Palella; Stuart Johnson; Eniola Obadina; Dennis W Raisch; Jorge P Parada
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.

Authors:  June M McKoy; Matthew J Fisher; D Mark Courtney; Dennis W Raisch; Beatrice J Edwards; Marc H Scheetz; Steven M Belknap; Steven M Trifilio; Athena T Samaras; Dustin B Liebling; Beatrice Nardone; Katrina Marie Tulas; Dennis P West
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

Review 5.  Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).

Authors:  Susan E Beekmann; David K Henderson
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

6.  Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report.

Authors:  Deniz Gökengin; Tansu Yamazhan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2002-09-16       Impact factor: 3.944

7.  Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.

Authors:  Rebecca Pavlos; Elizabeth J McKinnon; David A Ostrov; Bjoern Peters; Soren Buus; David Koelle; Abha Chopra; Ryan Schutte; Craig Rive; Alec Redwood; Susana Restrepo; Austin Bracey; Thomas Kaever; Paisley Myers; Ellen Speers; Stacy A Malaker; Jeffrey Shabanowitz; Yuan Jing; Silvana Gaudieri; Donald F Hunt; Mary Carrington; David W Haas; Simon Mallal; Elizabeth J Phillips
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

8.  Post-exposure prophylaxis following occupational exposure to HIV and hepatitis B: an analysis of a 12-year record in a Nigerian tertiary hospital.

Authors:  Salisu Abubakar; Garba Iliyasu; Farouq Muhammad Dayyab; Salisu Inuwa; Rabiu Alhassan Tudun Wada; Nasiru Magaji Sadiq; Muktar Ahmed Gadanya; Abdulrahman Abba Sheshe; Mohammad Sani Mijinyawa; Abdulrazaq Garba Habib
Journal:  J Infect Prev       Date:  2017-12-17

9.  Antiretroviral Therapy-associated Serious and Life-threatening Toxicities.

Authors:  Alice K. Pau
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.663
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.